Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFAMAB: rifabutin versus rifampicin for staphylococcal prosthetic joint infection treated with DAIR
2024-519894-20-01Phase 3Authorised
- Sponsor
- Centre Hospitalier de Tourcoing
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in periprosthetic joint infection (PJI) and Staphylococcal periprosthetic joint infection (SPJI) comparing Rifabutin arm with Rifampicin arm (2 arms). Primary endpoint: Treatment failure at 1 year. Planned start Feb 2025; status: authorised.
02
Drugs
rifabutinrifampicin
03
Conditions
periprosthetic joint infection (PJI)Staphylococcal periprosthetic joint infection (SPJI)
Beyond the preview
Go deeper on 2024-519894-20-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519894-20-01.